NORWEGIAN UNIVERSITY OF

SCIENCE AND TECHNOLOGY

Faculty of Medicine

Department of CLINICAL

AND

Molecular MediciNE

## 

## Curriculum Vitae

## Prof. Oluf Dimitri Røe, MD&PhD

## 

## Current affiliations

**1.Consultant Oncologist**

Department of Oncology

Levanger Hospital

Nord-Trøndelag Hospital Trust

Kirkegata 2, N-7600 Levanger

Norway

**Contact information**

**Telephone**

Private +47 73 90 06 50

Cellular +47 95 43 24 96

Levanger +47 74 09 80 00

NTNU +47 72 82 52 63

Fax +47 72 57 64 00

**Email**

[olufdroe@yahoo.no](mailto:olufdroe@yahoo.no)

[oluf.roe@ntnu.no](mailto:oluf.roe@ntnu.no)

**Private address**

Fjøsmestervegen 8c

7046 Trondheim, Norway

**2.Professor**

Department of Clinical and Molecular Medicine

Faculty of Medicine and Health Sciences

Norwegian University of Science and Technology (NTNU)

Prinsesse Kristinsgt. 1, N-7491 Trondheim

Norway

**3.Associate Professor**

Clinical Cancer Research Center

Department of Clinical Medicine

Aalborg University Hospital

Hobrovej 18-22

DK-9100 Aalborg

Denmark

**Websites** <http://www.mensxmachina.org/cancer_biomarker_hunt/>

<http://www.ntnu.edu/employees/oluf.roe>

<http://vbn.aau.dk/en/persons/oluf-dimitri-roee(be09261d-e409-4420-9ba9-858000211604).html>

## Personal

**Born:** Jan 13th 1962 in Namsos, Norway

**Citizenship:** Norwegian

**Civil status:** Married to Alexandra Angeletaki, cand mag. Archaeologist, two children born 1989 and 1993.

**Languages: Fluent;** English, Norwegian, Greek **Conversation;** Spanish, German

**Education**

1982 Basic Clinical and Theoretical Psychology, University of Trondheim, Norway

1983-89 Medical School Univ. of Bergen and University of Trondheim (currently named Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Norway

1989 Cand. Med. MD

1991 Licenced MD

1994 Licenced MD in Greece

2001-07 Oncology specialization, Dept. of Oncology, St. Olavs University Hospital, Trondheim, Norway

2007 Board Certified Specialist in Medical and Radiation Oncology

2003-2008 PhD student in Clinical Medicine

2008 Dissertation at the Faculty of Medicine, NTNU

Title of Thesis: ***Malignant mesothelioma: Virus, Biomarkers and Genes. A Translational Approach***

2010 Passed course in GCP

2013 Licenced Specialist in Oncology in Sweden, Denmark and Greece

2017 Course in University pedagogics for Professors, NTNU

2017 Course in supervision of medical students for Lecturers and Professors in Medicine

2019 Accepted title Professor at the NTNU

**Positions**

1990-91 Internship Gjøvik County Hospital, Gjøvik and Kautokeino Health Center, Kautokeino (Samiland), Norway

1992-94 General Practitioner in Kautokeino, Finnmark, Norway

1994-2001 General Practitioner in Mykonos, Greece (Norwegian/Greek MD licence)

2001-07 MD in specialization, Departments of Oncology/Haematology/Lung Diseases, St. Olavs University Hospital, Trondheim, Norway

2004-06 Assistant Consultant in Clinical Oncology, Department of Oncology, St. Olavs University Hospital, Trondheim, Norway

2006-10 Consultant Oncologist, Department of Oncology, St. Olavs University Hospital, Trondheim, Norway

Nov 2010- May 2011-Feb /Nov/Dec 2012 Research fellow translational research in mesothelioma and lung cancer,

Nanjing Medical University, Nanjing, China

May 2011- present Consultant Oncologist, Department of Oncology, Levanger Hospital, Levanger, Norway

2012- present Research Oncologist, Department of Clinical and Molecular Medicine,

Norwegian University of Science and Technology (NTNU) Trondheim, Norway

2012-2017 Post-doc, Department of Clinical and Molecular Medicine,

Norwegian University of Science and Technology (NTNU) Trondheim, Norway

July 2013- present Associate Professor and Consultant, Department of Oncology, Aalborg University Hospital,

January 2018- 2019 Associate Professor, Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway

November 2019 Professor, Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway

**Research interests**

My main research interests have been a combination of clinical and basic cancer research (translational), including biomarkers for early detection of cancer, predictive and prognostic biomarkers, genome-wide analysis, mechanisms of treatment resistance and risk prediction models for lung cancer.

The research has been focused on mesothelioma, an asbestos-related cancer, but recently also lung and gastric cancer. I have published papers on biomarkers in serum and tissue of mesothelioma and gastric cancer in international peer-reviewed journals as Journal of Thoracic Oncology, Lung Cancer, PlosOne, EBioMedicine, Clinical Cancer Research and Gut. Specifically in mesothelioma my research experience includes clinical research where I initiated and completed studies on early detection of mesothelioma in pre-clinical serum in collaboration with the Cancer Registry and the Janus Biobank, with a fruitful collaboration with prof. Jeanette Creaney at the National Centre for Asbestos Related Diseases, University of Western Australia, Perth, Australia. At our research department I conducted three gene expression studies at the FUGE (Functional Genomics) core facility with Affymetrix U133 Plus 2 and Illumina HumanHT-12 v3 Expression BeadChip on human mesothelioma and normal pleural samples.

The recent years a collaborative work on novel bioinformatics methods with bioinformaticians at the University of Crete in Greece has resulted in exciting results and new publications.

Since November 2010 a collaboration/visiting researcher/supervisor with Nanjing Medical University, China was initiated on mesothelioma, lung and gastric cancer.

As a collaborating/visiting researcher periodically at the Nanjing Medical University, I have co-authored 13 peer-reviewed papers, including in some high-impact journals as Cell Death and Disease, Gut, Clinical Cancer Research, Scientific Reports and Oncotarget (see full publication list).

There was a fruitful collaboration with the oncologists at the Nanjing Medical University Oncology Department with some publications (see publication list) and one independent collaboration with the Yuyao Peoples Hospital, Zheijiang Province, China and University of Tokyo, Japan as probably the first paper linking mesothelioma in women to occupational asbestos exposure in China **(Paper 35)**.

The prospective HUNT biobank in Levanger, Norway, is one of the largest biobanks in Scandinavia with serum and clinical data from approximately 120 000 subjects. Since May 2011 collaboration with the HUNT was initiated, aiming at tumour-specific microRNA discovery in pre-diagnostic serum. The Cancer-Biomarker-HUNT Project aims at discovery of biomarkers in serum for detection of lung cancer and mesothelioma in an early stage.

<http://www.mensxmachina.org/cancer_biomarker_hunt/>

Currently, we developed a novel validated clinical risk prediction model and online calculator for lung cancer, the HUNT Lung Cancer Model **(Paper 47)** which combined with GWAS and pre-diagnostic microRNA can refine the screening and diagnostic model. This project is designated EARLYSCREEN.

Since 2013- appointed as Clinical Associate Professor (20%) at the Aalborg University Hospital. Aalborg, the major and capital city in the Northern Jutland Region has hosted the only asbestos factory (Eternit) in Denmark and processed 80% of all asbestos imported to Denmark. The long term effects of the asbestos use is that the age-standardised incidence rate for men with mesothelioma in the Region of Northern Jutland in 2008-2009 is approximately 2-3-fold higher than in the other four Danish Regions, and we have newly discovered the environmental impact on the risk of mesothelioma in women **(Paper 49)** as well as showing for the first time germline cancer susceptibility genes in mesothelioma, in collaboration with University of Chicago **(Paper 50).** We recently identified and validated BAP1 loss as the first predictive biomarker for chemotherapy in mesothelioma **(Paper 70).** Currently I hold a position as Clinical Associate Professor at the Department of Oncology in Aalborg, and initiated a multidisciplinary group formed to do mesothelioma research.

Since 2018- I hold a 20% Professor position at the Department of Clinical and Molecular Research, NTNU, Trondheim, Norway.

**Funding**

**2012** Norwegian Research Council for collaborative project with China, 310 000 NoK

**2012** Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, post-doc position 60% for 5 years

**2014** Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, 5,7 mill. NoK for 4 years

**2015** Levanger Hospital, Nord-Trøndelag Hospital Trust, 300 000 Nok

**2016** BONNIE J. ADDARIO LUNG CANCER FOUNDATION AND INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC) JOINT AWARD 2016.

2,7 mill. NoK (300 000 USD) for two years, see

<https://www.iaslc.org/news/bonnie-j-addario-lung-cancer-foundation-and-international-association-study-lung-cancer>

**2017** PhD position for Olav Toai Duc Nguyen, 6 years 50% position 2018-2024 “EARLYSCREEN; validating a novel clinical and molecular early diagnostic lung cancer screening model in HUNT and CONOR”.

**2018** Liaison Committee between the Central Norway Regional Health Authority (RHA) and the NTNU, 2.9 mill. NoK for 3 years.

**Mobility**

**2017** Starting a research collaboration with NCI, Bethesda, Washington and AAU

**2017** Starting a research collaboration with University of Chicago and AAU

**2010-12** Research fellow (part time), Nanjing Medical University, Nanjing, China

**1994-2001** General Practitioner in Mykonos, Greece (Norwegian/Greek MD licence)

**1992-94** General Practitioner in Kautokeino, Finnmark, Norway

**Institutional responsibilities**

**2016-2018** Member of the National Specialist Group for assessment of new Lung Cancer drugs in Denmark, Medicinrådet.

**2015-2018** Leader of the Educational Board, Department of Oncology, Levanger Hospital, Norway.

**2008-10** Responsible for Thoracic and CNS cancer in Mid-Norway, St. Olavs Hospital, Trondheim, Norway

**2006-07** Responsible for Outpatient Palliative Patients, Department of Palliative Medicine, St. Olavs Hospital, Trondheim, Norway

**Comissions of trust / Chairman/ Reviewer**

**2018** Organizer/chairman of the **2nd International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: *From diagnosis to immunotherapy – why is precision medicine so difficult?***Trondheim, Norway

https://cancerbiomarkerstrondheim.com/

**2016** Organizer/chairman of the **1st International NTNU Symposium on Current and Future Clinical Biomarkers of Cancer: *Innovation and Implementation***, Trondheim, Norway, 100 attendees and invited speakers from 12 countries and 4 continents

<https://biomarkerstrondheim.wordpress.com/>

The excerpts of this symposium are published in the Journal of Translational Medicine, 2016.

**2005-18** Second leader of the Board of the Norwegian Oncological Society

**2008** Organizing Committee of the International Mesothelioma Interest Group, Amsterdam, Netherland

**2008-present** Chair at several international round tables on mesothelioma

**Reviewer for Journals**: “Plos One”, “Lung Cancer”, “Oncotarget”, “BMC Cancer”, “BMJ Open”, “DNA Repair”, “Current Cancer Therapy Reviews”, “Current Medicinal Chemistry”, “Differentiation”, “Journal of Experimental and Clinical Cancer Research”, “British Journal of Pharmacology”, “Oncology Reports”, “Journal of Thoracic Oncology” and “EBiomedicine”.

**Review Board:** Expert Reviewer HORIZON 2020, Expert Reviewer National Cancer Institute, USA, British Lung Foundation, Commission for Cancer Research Zurich, Fondation Contre le Cancer, Belgium, Austrian Science Fund (FWF).

**Memberships of scientific societies**

1991- Member of the Norwegian Medical Association

1994-2001 Member of the Greek Association of General Practitioners

2001- Member of the Norwegian Oncological Society

2003- Member of the International Mesothelioma Interest Group

2016- Member of the ASCO

2016- Member of the International Association for the Study of Lung Cancer (IASLC)

**Awards**

**2014 BI Cancer Research Award**

**For best Norwegian poster on lung cancer (Norwegian Lung Cancer Group);**

R Mjelle, T Andreassen, V Lagani, K Kerkentzes, I Tsamardinos, TF Bathen, E Larsson, **OD Røe**, “Hunting” for lung-cancer / mesothelioma early diagnostic biomarkers: results of a pilot analysis from the Cancer-Biomarker-HUNT study.

IMIG 2014, Cape Town

**2016** BONNIE J. ADDARIO LUNG CANCER FOUNDATION AND INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER (IASLC) JOINT AWARD 2016.

2,7 mill. NoK (300 000 USD) for two years, see

<https://www.iaslc.org/news/bonnie-j-addario-lung-cancer-foundation-and-international-association-study-lung-cancer>

**2018** iMig 2018 Best Poster Award at the 14th International Conference of the International Mesothelioma Interest Group (iMig 2018), Ottawa, Canada

**Asbestos use and pleural mesothelioma in Norway and Denmark:**

**Similar populations, different stories**

**Oluf Dimitri Røe,** Øyvind Omland Vasiliki Panou, Axel Wannag

**Collaborations**

**TIDL Early detection of lung cancer – PI Ass. Prof Haseem Ashraf, co-PI Oluf D. Røe**

**Cancer-Biomarkers in HUNT- and EARLYSCREEN projects- PI Oluf D. Røe**

National partners: Prof. Tone Frost-Bathen, Prof. Pål Sætrom, post-doc Robin Mjelle.

Prof Kristian Hveem and Prof Arnulf Langhammer, HUNT Research Center

Anna Nordborg, PhD, Dept. of Mass Spectrometry (MS), SINTEF Research Center, Trondheim

Prof. Ioannis Tsamardinos, University of Crete, Greece

Prof. Erik Larsson, Uppsala University, Sweden (deceased)

Prof. Åslaug Helland, The Norwegian Radiumhospital, Oslo, Norway

**Lung cancer-mesothelioma-gastric cancer in China and Japan- various collaborations**

Prof. Jianwei Zhou, Nanjing Medical University & Prof. Yijiang Chen, Thoracic Surgery Department, 1st Affiliated University Hospital, Nanjing, China

Dr. Gao Zhibin, MD PhD, Department of Pathology, Yuyao People’s Hospital, Yuyao, Ningbo, China

Prof. Kenzo Hiroshima, Department of Pathology, Tokyo Women’s Medical University Yachiyo Medical Center, Yachiyo, Japan

Kenji Morinaga, MD PhD, Department of Asbestos-related Health Damage Relief, Environmental Restoration and Conservation Agency of Japan, Saiwai-Ku, Kawasaki-Shi, Kanagawa, Japan

**Meso-HUNT Aalborg- PI Oluf D. Røe**

PhD Student Vasiliki Panou, MD, Prof. Mogens Vyberg, Prof. Øyvind Omland, Prof. Ursula Falkmer, Prof. Martin Bøgsted, Aalborg University Hospital, Aalborg, Denmark,

Prof. Hedy Kindler, Medical Director, Gastrointestinal Oncology

Director, Mesothelioma Program, University of Chicago, Chicago, USA

Prof. Jenette Creaney, UWA, Perth, Australia

Prof. Anna Nowak, UWA, Perth, Australia

**Predictive markers in lung cancer Aalborg- PI Oluf D. Røe**

PhD Student Weronika Szejniuk, Prof. Ursula Falkmer, Prof. Martin Bøgsted, Aalborg University Hospital, Aalborg, Denmark

Ana Robles, PhD and Curtis Harris, MD, National Cancer Institute, Bethesda, Washington DC, USA

**Mesothelioma translational project (previous)- PI Oluf D. Røe**

Senior Researcher Kristina Kjærheim, Norwegian Cancer Registry, Oslo

Prof. Bruce Robinson, Prof. Jeanette Creaney, National Center for Asbestos Related Diseases (NCARD), University of Western Australia, Perth, Australia

Paolo Boffetta, IARC, Lyon, France /Mount Sinai, NY, USA

Prof. Michael Pawlita, Research Program Infection and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany

Ass Prof Katalin Dobra, Department of Pathology, Karolinska, Stockholm, Sweden

Yrr Mørch PhD, Group of Polymer Particles and Surface Chemistry Nanolab, SINTEF Research Center, Trondheim

**Teaching**

2009-present Lectures at annual and biannual Nordic and Greek thoracic oncology meetings

2010-present Teaching medical students and censor for master students, medical students and elected board member for one PhD student at the IKM, NTNU, Trondheim, Norway

2010- Teaching as part of visiting researcher at the Nanjing Medical University (NMU), Nanjing, China

2013- Teaching PhD students continuously and at annual PhD courses at the Department of Oncology, Aalborg University Hospital, Aalborg, Denmark

2013-2018 Leader and organizer of the curriculum and teaching of the doctors specializing in oncology at the Levanger Hospital, Levanger, Norway

2014 Contribution of one paper to the PhD thesis of Adam Szulkin , Dissertation at the Karolinska Institute, Title: CHARACTERIZATION OF MALIGNANT PLEURAL MESOTHELIOMA: POSSIBILITIES FOR AN INDIVIDUALIZED THERAPEUTIC ARSENAL

2018 Contribution of one paper to the PhD thesis of Laurids Ø. Poulsen, Title: Diagnostic, Predictive and Therapeutic Aspects on Adenocarcinoma of the Rectum

**Supervision**

**PhD theses** (2010- present)

2010-2014 Two PhD students finalized their PhD in Nanjing, China 2014

At the group of Prof. Jianwei Zhou, I was a co-mentoring two PhD students, Drs. Yensu Chen and Wenxia Xu

**The title of their PhD was:**

**1. Yensu Chen:** “The mechanism of JWA inhibiting tumor angiogenesis in gastric cancer.”

**2. Wenxia Xu:** “The molecular mechanisms of resistance and reversal of resistance to cisplatin in human gastric cancer cells.”

***See attached attestation from Prof. Jianwei Zhou.***

**Main supervisor three PhD-students**

**1.** Vasiliki Panou, MD, PhD, Department of Pulmonary Medicine, Aalborg University Hospital***Title:Prognostic and predictive biomarkers for Malignant Pleural Mesothelioma, MESO-HUNT-AALBORG***

Succesful dissertation June 2019.

**Paper 1.The established and future biomarkers of malignant pleural mesothelioma**

**V Panou**, M Vyberg, U M Weinreich, C Meristoudis, U Falkmer, **O D Røe**

*Cancer Treatment Reviews, May 2015, doi*[*http://dx.doi.org/10.1016/j.ctrv.2015.05.001*](http://dx.doi.org/10.1016/j.ctrv.2015.05.001)

**Paper 2.** [**Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.**](https://www.ncbi.nlm.nih.gov/pubmed/30113886)

**Panou V**, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, **Røe OD**, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE.

J Clin Oncol. 2018 Aug 16:JCO2018785204. doi: 10.1200/JCO.2018.78.5204.

**[Paper 3.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)** [**[Panou V](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**](https://www.ncbi.nlm.nih.gov/pubmed/?term=Panou%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[1](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Vyberg M](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Vyberg%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Meristoudis C](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meristoudis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Hansen J](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Bøgsted M](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%B8gsted%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Omland Ø](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Omland%20%C3%98%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Weinreich UM](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Weinreich%20UM%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[**[Røe OD](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**](https://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)**[.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**

[Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland, Denmark.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)

[Scand J Work Environ Health.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.) 2018 Jul 19. pii: 3756. doi: 10.5271/sjweh.3756.

Eight abstracts published (see below).

**2.** Weronika Szejniuk, MD, PhD, Department of Oncology, Aalborg University Hospital

***Title: Non-coding RNAs as predictive biomarkers for adjuvant chemotherapy in non-small cell lung carcinoma. Discovery and Validation Study****.*Department of Oncology, Aalborg University Hospital,

Dissertation June 2021.

**Paper 1.** **Szejniuk WM**, Robles AI, McCulloch T, Falkmer UGI, **Røe OD**.

[Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art.](https://www.ncbi.nlm.nih.gov/pubmed/30190521)

Pharmacogenomics J. 2018 Sep 7. doi: 10.1038/s41397-018-0029-1. Review.

**Paper 2.** Szejniuk WM, Nielsen MS, Brønnum D, Takács-Szabó Z, Weinreich UM, Pilegaard Thomsen L, Bøgsted M, Jensen I, McCulloch T, Falkmer UG, Carl J, **Røe OD**

Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: a pilot study.  
Clinical and Translational Radiation Oncology 2019 <https://doi.org/10.1016/j.ctro.2019.09.004>

**Paper 3.** WM Szejniuk, M Cekala, M Bøgsted, C Meristoudis, T McCulloch, UG Falkmer, **OD Røe**

Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay

[Cancer Treatment and Research Communications](https://www.sciencedirect.com/science/journal/24682942) [Volume 27](https://www.sciencedirect.com/science/journal/24682942/27/supp/C), 2021, 100318

<https://www.sciencedirect.com/science/article/pii/S2468294221000174>

**3.** Olav Toai Duc Nguyen, MD, Levanger Hospital and Department of Clinical and Molecular Medicine, NTNU, Norway. **Title: EARLYSCREEN: Validating a novel clinical and molecular early diagnostic screening model in HUNT and CONOR.**

**Paper 1.** Untargeted Metabolomics Discovers Biomarkers in Serum Months to Years Before Lung Cancer and Mesothelioma (in progress)

**Paper 2.** Untargeted Proteomics Discovers Biomarkers in Serum Months to Years Before Lung Cancer and Mesothelioma (in progress)

Expected completed 2020.

**Co-supervisor one PhD-student**

**1.** Karen Sofie Bunemann Dalsgaard, MD, (completed) Title: ***Environmental asbestos exposure in four primary schools in Aalborg, Denmark and cancer in adulthood.*** Department of Occupational Medicine, Aalborg University Hospital

Accepted: **Environmental asbestos exposure in childhood and the risk of mesothelioma later in life. A long-term follow-up register based cohort study.** Sofie Bünemann Dalsgaard, Else Toft Würtz, Johnni Hansen Oluf Dimitri Røe, Øyvind Omland

Successful dissertation May 2019

All protocols have been developed in collaboration with the PhD candidates.

We have regular 2-day PhD-courses at Klitgaarden, Skagen, Denmark where I co-organize, teach and supervise as part of a team.

**Supervision of Post-doc** (2015-2018)

Supervision of post-doc Robin Mjelle at the NTNU in our Cancer-Biomarkers in HUNT project.

**Medical student theses** (2014- present)

2 finalised:

**1.** Candidate: Stud med Ida Nielsen (passed examination the 20th of January 2016). Initiated/supervised one medical student thesis at the Aalborg University Hospital ***Treatment and survival of patients with malignant pleura mesothelioma in North Jutland in the period 2002-2013, a retrospective analysis* (also published abstract at ASCO 2016)**

**2.** Candidate Stud med Marius Hvidsten (passed examination August 2018), NTNU: Medical student thesis at the NTNU entitled: ***Asbestos and mesothelioma: Studies of the scientific literature in USSR and Russia compared to the World literature.***

**Invited speaker**

* Pathology Spring Meeting 2008, Uppsala, Sweden **Genprofilering av mesotheliom och normal pleura; överuttryck av vissa gener kan förklara strålnings och cytostatikaresistens.**
* Hellenic Oncological Society 2009, Heraklion, University of Crete, Greece **Malignant mesothelioma, chemo-and radio- resistance related to gene expression**
* MOLMED 2010, Shangai, China **Mesothelioma and treatment resistance: What can we learn from gene expression?**
* Nanjing Medical University, 15. Nov. 2010, Nanjing, China **Mesothelioma- a forgotten epidemic**
* Nanjing Medical University, Dec. 2012, Nanjing, China **MicroRNA in Cancer**
* CancerScience/Biomarker meeting, Nov. 2013, San Francisco, USA **Biomarker HUNT in asbestos related diseases**
* 2rd “Symposium on Thoracic and Upper Aerodigestive Malignancies” , 2013, Athens, Greece **Mesothelioma, pathophysiology and epidemiology**
* Springmeeting Lungcancer 15th May 2014, Oslo, Norway **Mesothelioma- New research of a forgotten epidemic**
* “MicroRNAs/Noncoding RNAs Europe 2014, November 3 - 4, 2014 University of Cambridge, Cambridge, United Kingdom **MicroRNAs in serum for early diagnosis of cancer. Where are we?**
* 3rd “Symposium on Thoracic and Upper AerodigestiveMalignancies” February 5-7, 2015 Athens, Greece **Biomarkers for early diagnosis of lung cancer and mesothelioma**

* 2nd NordiQC Conference on Applied Immunohistochemistry, June 9th - 12th 2015 Aalborg, Denmark **Malignant mesothelioma – epidemiology and molecular biology**
* “MicroRNAs/Noncoding RNAs & Genome Editing Europe 2015” meeting, Cambridge, UK, 2 -3. November 2015. **Early diagnosis of lung cancer and mesothelioma by multi-omics, techniques and feasibility**
* Translational oncology meeting, Heraklion Crete, 16. Nov. 2016 **Early diagnosis of lung cancer-the Cancer in Biomarkers in HUNT project**
* 4th “Symposium on Thoracic and Upper AerodigestiveMalignancies” April 7-8, 2015 Athens, Greece **Circulating biomarkers for mesothelioma**
* 5th “Symposium on Thoracic and Upper AerodigestiveMalignancies” April, 2017 Athens, Greece **Prognostic factors for mesothelioma**
* Thoracic oncology dept., Bank of Cyprus Cancer Center, Nicosia, Cyprus, May 04 2017 **Asbestos, lung cancer and mesothelioma – Status, future and current research**
* Laboratory of Carcinogenesis, National Cancer Institute (NCI), Bethesda, Washington, USA, June 07th 2017 **Asbestos, lung cancer and mesothelioma – Status, future and current research**
* Association of palliative nurses of North Denmark, Aalborg, April 17, 201Asbest, **Lungekræft og mesotheliom – Historie, status, forskning og fremtid.**
* Nordic Thoracic Oncology Group (NTOG) Vasa, Finland, April 22.2018 **MesotheliomaBiomarkers**
* Nordic Thoracic Oncology Group (NTOG) Stockholm, Sweden, Feb 1st.2019 **Mesothelioma Biomarkers and Targets**
* Perkins Institute, University of Western Australia, Perth, Australia, Nov 2019 **Early detection biomarkers in lung cancer and mesothelioma**
* **PhD course NTNU, Oct 2022, From tumor type to sequencing.**

**Oluf Dimitri Røe, peer-reviewed work 2007-2023**

**Thesis**

**Røe OD, Malignant Mesothelioma: Virus, Biomarkers and Genes - a Translational Approach.** PhD Thesis. Norwegian University of Science and Technology, Faculty of Medicine, Institute of Cancer Research and Molecular Medicine & Institute of Laboratory Medicine, Children's and Women's Health, Trondheim 2008. Dissertations at the Faculty of Medicine, ISSN 0805-7680; 370 ISBN 978-82-471-1248-9

**Book Chapters**

Muzaffer Metintaş, Guntulu Ak, **Oluf Dimitri Røe**, Chapter 80 B.Malignant pleural mesothelioma Airway Diseases Editors: Cemal Cingi - Arzu Yorgancıoğlu - Nuray Bayar Muluk - Alvaro C Cruz, Springer 2023

**Røe OD, Stella GM,** Malignant pleural mesothelioma- history, controversy, and future of a man-made epidemic.Springer Verlag, “Asbestos and Mesothelioma” edited by Joseph Testa, Fox Chase Cancer Center, USA. ISBN 978-3-319-53560-9, © 2017

**2024**

**77.** Nguyen OTD, Fotopoulos I, Markaki M, Tsamardinos I, Lagani V, **Røe OD**,

Improving lung cancer screening selection: the HUNT Lung Cancer Risk Model for ever-smokers versus the NELSON and 2021 USPSTF criteria in the Cohort of Norway (CONOR), a Populationbased Prospective Study

JTO Clinical and Research Reports (2024), doi: https://doi.org/10.1016/ j.jtocrr.2024.100660.

**76.** Yuce TH, Ak G, Metintas S, Dundar E, **Røe OD**, Panou V, Metintas M,

BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma. *J Cancer Res Clin Oncol*. 2024;150(2):38. Published 2024 Jan 27. doi:10.1007/s00432-023-05565-6

**2023**

**75.** Johan Bjerner, Ola Bratt, Kirsti Aas, Peter C Albertsen, Sophie D Fosså, Rune Kvåle, Hans Lilja, Christoph Müller, Stig Müller, Andreas Stensvold, Owen Thomas, **Oluf D Røe**, Andrew Vickers, Jochen Walz, Sigrid V Carlsson Jan Oldenburg

Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium

Eur Urol 2023 May 9;S0302-2838(23)02791-4. doi: 10.1016/j.eururo.2023.04.028.

Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium

**74.** van Zandwijk N, Amos CI, **Røe OD**, Reid G, Klebe S,

Exon20-mutated NSCLC: Extending the dataset to allow the recognition of potential causes.

JTO Clinical and Research Reports (2023), doi: https://doi.org/10.1016/j.jtocrr.2023.100500.

**2022**

**73.** TH Nøst, AH Skogholt , I Urbarova, R Mjelle, E Paulsen, T Dønnem, Sigve Andersen, M Markaki, **OD Røe**, M Johansson, M Johansson, BH Grønberg, T Sandanger, P Saetrom

Increased levels of microRNA-320 in blood serum and plasma is associated with imminent and advanced lung cancer

Mol Oncol. 2022 Nov 7. doi: 10.1002/1878-0261.13336. Online ahead of print.

**72.** Louise Andersen Lynggård, VasilikiPanou, WeronikaSzejniuk, **Oluf DimitriRøe**, ChristosMeristoudis

Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma.

Journal of the American Society of Cytopathology <https://doi.org/10.1016/j.jasc.2022.07.003>

**71.** Ling Ma, Guosheng Chen, Deqiang Wang, Kai Zhang, Fengjiao Zhao, Jie Tang, Jianyi Zhao, **Oluf D. Røe**, Shaohua He, Dongcheng Liao, Yanhong Gu, Min Tao, Yongqian Shu, Wei Li, Chen Xiaofeng

A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy

Front. Oncol. Sec.Gastrointestinal Cancers: Gastric & Esophageal Cancers

doi: 10.3389/fonc.2022.893998

**70**. Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, Lee YCG, Dick IM, Firth T, Lynggaard LA, Asghari AB, Vyberg M, Hansen J, Creaney J, **Røe OD.**

[BAP1 loss by immunohistochemistry predicts improved survival to first line platinum/pemetrexed chemotherapy for pleural mesothelioma patients: A validation study.](https://pubmed.ncbi.nlm.nih.gov/35489694/)

J Thorac Oncol. 2022 Apr 27:S1556-0864(22)00210-6. doi: 10.1016/j.jtho.2022.04.008. Online ahead of print.PMID: 35489694

**69.** Dalsgaard SB, Würtz ET, Hansen J, **Røe OD**, Omland Ø

[A Cohort Study on Cancer Incidence among Women Exposed to Environmental Asbestos in Childhood with a Focus on Female Cancers, including Breast Cancer.](https://pubmed.ncbi.nlm.nih.gov/35206274/)

Int J Environ Res Public Health. 2022 Feb 13;19(4):2086. doi: 10.3390/ijerph19042086.PMID: 35206274

**2021**

**68.** Dalsgaard SB, Würtz ET, Hansen J, **Røe OD**, Omland Ø.[Cancer Incidence and Risk of Multiple Cancers after Environmental Asbestos Exposure in Childhood-A Long-Term Register-Based Cohort Study.](https://pubmed.ncbi.nlm.nih.gov/35010531/)

Int J Environ Res Public Health. 2021 Dec 27;19(1):268. doi: 10.3390/ijerph19010268.PMID: 35010531

**67.** Papoutsoglou G, Karaglani M, Lagani V, Thomson N, **Røe OD**, Tsamardinos I, Chatzaki [Automated machine learning optimizes and accelerates predictive modeling from COVID-19 high throughput datasets.](https://pubmed.ncbi.nlm.nih.gov/34302024/)

E.Sci Rep. 2021 Jul 23;11(1):15107. doi: 10.1038/s41598-021-94501-0.PMID: 34302024

**66**. Szejniuk WM, Nielsen MS, Takács-Szabó Z, Pawlowski J, Al-Saadi SS, Maidas P, Bøgsted M, McCulloch T, Frøkjær JB, Falkmer UG, **Røe OD.**

[High-dose thoracic radiation therapy for non-small cell lung cancer: a novel grading scale of radiation-induced lung injury for symptomatic radiation pneumonitis.](https://pubmed.ncbi.nlm.nih.gov/34266462/)

Radiat Oncol. 2021 Jul 15;16(1):131. doi: 10.1186/s13014-021-01857-8.PMID: 34266462

**65.** WM Szejniuk, M Cekala, M Bøgsted, C Meristoudis, T McCulloch, UG Falkmer, **OD Røe**

Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose-intensity and treatment delay

[Cancer Treatment and Research Communications](https://www.sciencedirect.com/science/journal/24682942) [Volume 27](https://www.sciencedirect.com/science/journal/24682942/27/supp/C), 2021, 100318

<https://www.sciencedirect.com/science/article/pii/S2468294221000174>

**64.** Thomas Ringgaard Petersen, Vasiliki Panou, Christos Meristoudis, Ulla Møller Weinreich, **Oluf Dimitri Røe**

Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting

Acta Oncol. 2021 Jan 27;1-7. doi: 10.1080/0284186X.2021.1876246. Online ahead of print.

**2020**

**63. Røe OD**

Democratic and ethical problem of lung cancer screening: exclusion of true high-risk populations. Can it be fixed? Yes

BMJ Open Respir Res. 2020 Dec;7(1):e000811. doi: 10.1136/bmjresp-2020-000811.

**62.** Nguyen O.T.D., Sundstrøm S.H., Westvik G.S., Røttereng A.K.S., Melhus M.R., Bergseth C., Hallem E.K., **Røe O.D**

Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report

Case Rep Oncol 2020;13:1059–1066

<https://doi.org/10.1159/000509747>

**61.** Panou V, **Røe OD.**

Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.

Int J Mol Sci. 2020 Jun 17;21(12):4327. doi: 10.3390/ijms21124327.

PMID: 32560575

**60.** E. Wurtz, J. Hansen, **O.D. Røe**, Ø. Omland

Asbestos exposure and haematological malignancies – a Danish cohort study"

*Eur J Epidemiol 2020 Feb 10.*

*doi: 10.1007/s10654-020-00609-4. Online ahead of print.*

**2019**

# 59. Oluf Dimitri Røe, MD, PhD1,2,3 Maria Markaki, PhD4, Ioannis Tsamardinos, PhD4,5,6, Vincenzo Lagani, PhD6,11, Jesper Holst Pedersen, MD, PhD7, Zaigham Saghir8, MD, PhD, Haseem Ashraf MD, PhD8,9,10. A "Reduced" HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.

2019 BMJ Open Respiratory Research<https://bmjopenrespres.bmj.com/content/6/1/e000512.abstract>.

**58.** Dr. Kleanthi Lakiotaki , Prof. George Georgakopoulos , Prof. Elias Castanas , **Dr. Oluf Dimitri Røe** , Dr. Giorgos Borboudakis, Prof. Ioannis Tsamardinos

A data driven approach revealing disease similarity on a molecular level

npj Systems Biology and Application 2019 <https://www.nature.com/articles/s41540-019-0117-0>

**57.** Editors1 and Organizers2: Ana I. Robles1, Magne Børset2, Anders Sundan2, Anne-Marit Sponaas1,2, **Oluf Dimitri Røe1,2**

Abstracts from the 2nd International Norges Teknisk-Naturvitenskapelige Universitet (NTNU) Symposium: Day 2—biomarkers in precision diagnosis and treatment

Current and Future Clinical Biomarkers of Cancer: From diagnosis to immunotherapy—why is precision medicine so difficult?

Oncogene (2019) <https://www.nature.com/articles/s41388-019-1048-3>

**56.** Szejniuk WM, Nielsen MS, Brønnum D, Takács-Szabó Z, Weinreich UM, Pilegaard Thomsen L, Bøgsted M, Jensen I, McCulloch T, Falkmer UG, Carl J, **Røe OD**

Fractional exhaled nitric oxide as a potential biomarker for radiation pneumonitis in patients with non-small cell lung cancer: a pilot study.  
Clinical and Translational Radiation Oncology 2019 <https://doi.org/10.1016/j.ctro.2019.09.004>

**55.** **Oluf Dimitri Røe**, Kenji Chamoto, Tasuku Honjo, Madhav V. Dhodapkar, Alexander Lesokhin, Rui Yang, Andrew Mellor, Lei Huang, Henrique Lemos, Kavita Dhodapkar, Conad Rauber, Laurence Zitvogel, Johanna Olweus, Ole Audun Werner Haabeth, Even H. Rustad, Magne Børset, Anders Sundan, Robert Peter Gale, Anne-Marit Sponaas

Excerpts from the 2nd International NTNU Symposium, Current and Future Clinical Biomarkers of Cancer: From diagnosis to immunotherapy – why is precision medicine so difficult? Day 1-Hematology.

Leukemia 2019 <https://www.nature.com/articles/s41376-019-0004-5>

**54.** Environmental asbestos exposure in childhood and the risk of mesothelioma later in life. A long-term follow-up register based cohort study. Sofie Bünemann Dalsgaard, Else Toft Würtz, Johnni Hansen **Oluf Dimitri Røe**, Øyvind Omland

2018 [Occup Environ Med.](https://www.ncbi.nlm.nih.gov/pubmed/30804166) 2019 Feb 25. doi: 10.1136/oemed-2018-105392

**2018**

**53.** **Røe OD,** Asbestos and mesothelioma in Denmark 2017: status of a man-made cancer epidemic.

Ugeskr Læger 2018;180:V02180128

**52.** Rangul V, Sund ER, Mork PJ, **Røe OD**, Bauman A.

The associations of sitting time and physical activity on total and site-specific cancer incidence: Results from the HUNT study, Norway

PLoS One. 2018 Oct 23;13(10):e0206015. doi: 10.1371/journal.pone.0206015. eCollection 2018.

**51.** Szejniuk WM, Robles AI, McCulloch T, Falkmer UGI, **Røe OD**.

[Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art.](https://www.ncbi.nlm.nih.gov/pubmed/30190521)

Pharmacogenomics J. 2018 Sep 7. doi: 10.1038/s41397-018-0029-1. [Epub ahead of print] Review.

**50.** Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, **Røe OD**, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE.

[Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.](https://www.ncbi.nlm.nih.gov/pubmed/30113886)

J Clin Oncol. 2018 Aug 16:JCO2018785204. doi: 10.1200/JCO.2018.78.5204.

**[49.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**[[Panou V](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Panou%20V%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[1](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Vyberg M](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Vyberg%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Meristoudis C](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Meristoudis%20C%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Hansen J](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hansen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Bøgsted M](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=B%C3%B8gsted%20M%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Omland Ø](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Omland%20%C3%98%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[[Weinreich UM](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)](https://www.ncbi.nlm.nih.gov/pubmed/?term=Weinreich%20UM%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)[,](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)[**[Røe OD](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**](https://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=30025147)**[.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)**

[Non-occupational exposure to asbestos is the main cause of malignant mesothelioma in women in North Jutland, Denmark.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.)

[Scand J Work Environ Health.](https://www.ncbi.nlm.nih.gov/pubmed/30025147" \o "Scandinavian journal of work, environment & health.) 2018 Jul 19. pii: 3756. doi: 10.5271/sjweh.3756.

**48. Røe OD.** Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers? June 2018, Journal of Thoracic Disease 10(S16):S1956-S1961 DOI: 10.21037/jtd.2018.06.12

**47.** [Markaki M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Markaki%20M%5BAuthor%5D&cauthor=true&cauthor_uid=29678673), [Tsamardinos I](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tsamardinos%20I%5BAuthor%5D&cauthor=true&cauthor_uid=29678673), [Langhammer A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Langhammer%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29678673), [Lagani V](https://www.ncbi.nlm.nih.gov/pubmed/?term=Lagani%20V%5BAuthor%5D&cauthor=true&cauthor_uid=29678673), [Hveem K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hveem%20K%5BAuthor%5D&cauthor=true&cauthor_uid=29678673), [**Røe OD**](https://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=29678673)**.**

A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study.

[EBioMedicine.](https://www.ncbi.nlm.nih.gov/pubmed/29678673) 2018 Mar 30. pii: S2352-3964(18)30114-2. doi: 10.1016/j.ebiom.2018.03.027. [Epub ahead of print]

**2017**

**46. Røe OD.** Mesothelioma and mesothelin—an underused diagnostic biomarker becoming a treatment target, Shanghai Chest doi: 10.21037/shc.2017.11.07

**45.** J Sun, S He, P Lin, P Li,X Cai,L Li,J Qian,C Liu,X Li,Y Liu,**OD Røe,**Y ShuX Chenand Y Gu

Adjuvant Capecitabine and Oxaliplatin vs. Capecitabine and Paclitaxel in Gastric Cancer Patients after D2 Gastrectomy, Journal of Carcinogenesis & Mutagenesis, 8:306. doi: 10.4172/2157-2518.1000306

**44.** Wang Q, Chen Q, Zhu L, Chen M, Xu W, Panday S, Wang Z, Li A, Røe OD, Chen R, Wang S, Zhang R, Zhou J

Oncogenesis. 2017 Jul 3;6(7):e353. doi: 10.1038/oncsis.2017.57.

JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells.

**43. Røe OD,** Wahl GF, The undifferentiated carcinoma that became a melanoma: Why re-biopsy a CUP? A case report.

Journal of Medical Case Reports, Feb 2017 DOI: 10.1186/s13256-017-1238-y

**2016**

**42.** [**OD Røe**](http://jamanetwork.com/searchresults?author=Oluf+Dimitri+R%c3%b8e&q=Oluf+Dimitri+R%c3%b8e)

The High Cost of New Cancer Therapies—A Challenge of Inequality for All Countries

*JAMA Oncol.*Published online December 29, 2016. doi:10.1001/jamaoncol.2016.6335

**41.** Ana I. Robles, Karina Standahl Olsen, Dana W.T. Tsui, Vassilis Georgoulias, Jenette Creaney, Katalin Dobra, Mogens Vyberg, Nagahiro Minato, Robert A. Anders, Anne-Lise Børresen-Dale, Jianwei Zhou, Pål Sætrom, Boye Schnack Nielsen, Michaela B. Kirschner, Hans E. Krokan, Vassiliki Papadimitrakopoulou, Ioannis Tsamardinos and **Oluf D. Røe**

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

Journal of Translational Medicine201614:295 DOI: 10.1186/s12967-016-1059-6

**40.** J Qian, [W Zhu](http://www.pubpdf.com/search/author/Weiyou+Zhu), [K Wang](http://www.pubpdf.com/search/author/Keming+Wang), [L Ma](http://www.pubpdf.com/search/author/Lin+Ma), [J Xu](http://www.pubpdf.com/search/author/Jin+Xu), [T Xu](http://www.pubpdf.com/search/author/Tongpeng+Xu), [**OD Røe**](http://www.pubpdf.com/search/author/Oluf+Dimitri%20R%C3%B8e), [A Li](http://www.pubpdf.com/search/author/Aiping+Li),[J Zhou](http://www.pubpdf.com/search/author/Jianwei+Zhou), [Y Shu](http://www.pubpdf.com/search/author/Yongqian+Shu), [JWA LOSS PROMOTES CELL MIGRATION AND CYTOSKELETAL REARRANGEMENT BY AFFECTING HER2 EXPRESSION AND IDENTIFIES A HIGH-RISK SUBGROUP OF HER2-POSITIVE GASTRIC CARCINOMA PATIENTS.](http://www.pubpdf.com/pub/27167206/JWA-loss-promotes-cell-migration-and-cytoskeletal-rearrangement-by-affecting-HER2-expression-and-ide)

Oncotarget 2016 May 6. Epub 2016 May 6.

**39.** Q Li, X Zhi, J Zhou, R Tao, **OD Røe**, J Zhang, P Chen, L Sun, L Ma

Circulating Tumor Cells as a prognostic and predictive marker in Gastrointestinal Stromal Tumors: a Prospective Study,

Oncotarget. 2016 May 2. doi: 10.18632/oncotarget.9128.

**38.** Chen XF, Qian J, Pei D, Zhou C, **Røe OD**, Zhu F, He SH, Qian YY, Zhou Y, Xu J, Xu J, Li X, Ping GQ, Liu YQ, Wang P, Guo RH, Shu YQ.

Prognostic value of peri-operative leukocyte count in resectable gastric cancer.

|  |  |
| --- | --- |
|  |  |
|  | World J Gastroenterol. Mar 7, 2016; 22(9): 2818-2827 doi: 10.3748/wjg.v22.i9.2818 |

**37.** Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, **Røe OD**, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X

A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy

Drug Design, Development and Therapy, 2016 Feb [Volume 2016:10](https://www.dovepress.com/drug-design-development-and-therapy-archive19-v984) Pages 241—258

**36.** [Zhi X](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhi%20X%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Jiang B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Jiang%20B%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Yu J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Yu%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Qin J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Qin%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Ni Q](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ni%20Q%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Sun L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sun%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Xu M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Xu%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Zhu J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhu%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26891953), [Ma L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ma%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26891953)

Prognostic role of microscopically positive margins for primary gastrointestinal stromal tumors: a systematic review and meta-analysis.

[Sci Rep.](http://www.ncbi.nlm.nih.gov/pubmed/?term=PMID%3A+26891953) 2016 Feb 19;6:21541. doi: 10.1038/srep21541.

**2015**

**35.** Z Gao, K Hiroshima, X Wu, J Zhang, D Shao, H Shao, H Yang, T Yusa, T Kiyokawa, M Kobayashi, Y Shinohara, **OD Røe**, X Zhang, K Morinaga

Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China

*American Journal of Industrial Medicine, 29 May 2015 doi 10.1002/ajim.22494*

**34.** V Panou, M Vyberg, U M Weinreich, C Meristoudis, U Falkmer, **O D Røe**

The established and future biomarkers of malignant pleural mesothelioma

*Cancer Treatment Reviews, May 2015, doi*[*http://dx.doi.org/10.1016/j.ctrv.2015.05.001*](http://dx.doi.org/10.1016/j.ctrv.2015.05.001)

**33.** **OD Røe,** GM Stella Malignant pleural mesothelioma- history, controversy, and future of a man-made epidemic; review.

[*Eur Respir Rev.*](http://www.ncbi.nlm.nih.gov/pubmed/25726562)*2015 Mar;24(135):115-131.*

**32.** [Zhu W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zhu%20W%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Wu C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20C%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Li W](http://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20W%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Guo R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Guo%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Gu Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Liu Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Shu Y](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shu%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=25735792), [Chen X](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20X%5BAuthor%5D&cauthor=true&cauthor_uid=25735792).

Pemetrexed-platinum regimen as first-line chemotherapy for adenocarcinoma of the lung with asymptomatic and inoperable brain metastasis: a retrospective study

[*J Chemother.*](http://www.ncbi.nlm.nih.gov/pubmed/25735792)*2015 Mar 3:1973947815Y0000000005. [Epub ahead of print]*

**2014**

**31.** W Xu, Q Chen, Q Wang, Y Sun, S Wang, A Li, S Xu, **OD Røe**, M Wang, R Zhang, L Yang, J Zhou. JWA reverses cisplatin resistance via the CK2—XRCC1 pathway in human gastric cancer cells

*Cell Death and Disease (2014)****5****, e1551; doi:10.1038/cddis.2014.517*

**30.** H Cao, Q Zhou, R Lan, **OD Røe**, X Chen, Y Chen, D Wang

A functional polymorphism C-509T in TGFβ-1 promoter contributes to susceptibility and prognosis of lone atrial fibrillation in Chinese population.

*PLoS One. 2014 Nov 17;9(11):e112912. doi: 10.1371/journal.pone.0112912.*

**29. Røe OD,** Oppegaard PA, Revheim ME, Svindland A

Adrenocortical cancer mimicking lung cancer and responding to vinorelbine, pemetrexed and carboplatin- a case report

*BMJ Case Rep. 2014 Nov 12;2014. pii: bcr2014206225. doi: 10.1136/bcr-2014-206225.*

**28.** K Kerkentzes, V Lagani, M Vyberg, I Tsamardinos, **OD Røe**

Hidden treasures in “ancient” microarrays: Gene expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.

*Front. Oncol. 4:251. doi:10.3389/fonc.2014.00251*

**27.** Szejniuk WM, McCullock T, **Røe OD**

Effective ultra-low doses of erlotinib in patients with EGFR sensitizing mutation.

*BMJ Case Rep. 2014 Jul 23;2014. pii: bcr2014204809. doi: 10.1136/bcr-2014-204809.*

**26.** X Chen, Q Zhu, Y Liu, P Liu, YYin, R Guo, K Lu, Y Gu, L Liu, J Wang, Z Wang, **OD Røe,** Y Shu, L Zhu

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study

*PLoS One. 2014 May 16;9(5):e95897. doi: 10.1371/journal.pone.0095897. eCollection 2014.*

**25.** J Zhou, W Xu, S Wang, Q Chen, Y Zhang, P Ni, X Wu, J Zhang, F Qiang, A Li, **OD Røe**, S Xu, M Wang, and R Zhang. TXNL1-XRCC1 pathway regulates cisplatin induced cell death and contributes to resistance in human gastric cancer"

*Cell Death Dis. 2014 Feb 13;5:e1055. doi: 10.1038/cddis.2014.27*

**24.** Cao H, Zhu J, Xi L, **Røe OD**, Chen Y, Wang D. [Preoperative Serum Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Predict Stabilization of Spontaneously Restored Sinus Rhythm in Persistent Atrial Fibrillation Patients after Mitral Valve Surgery.](http://www.ncbi.nlm.nih.gov/pubmed/24434592) *Cardiology. 2014 Jan 14;127(3):183-189. PMID: 24434592*

**23.** Cao H, Wu Y, Li Q, Wu Y, Zhou Q, **Røe OD**, Chen Y, Wang R, Wang D.

[Serum sRANKL/OPG predict recurrence after radiofrequency catheter ablation of lone atrial fibrillation.](http://www.ncbi.nlm.nih.gov/pubmed/24326209)

*Int J Cardiol. 2014 Jan 1;170(3):298-302. doi: 10.1016/j.ijcard. PMID:24326209*

**2013**

**22.** [Huang Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Huang%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Wang W](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20W%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Chen Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Huang Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Huang%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Zhang J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [He S](https://www.ncbi.nlm.nih.gov/pubmed/?term=He%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Tan Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Tan%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Qiang F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Qiang%20F%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Li A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Li%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [**Røe OD**](https://www.ncbi.nlm.nih.gov/pubmed/?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=24127074)**,** [Wang S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Wang%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Zhou Y](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhou%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=24127074), [Zhou J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24127074).

The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients.

[J Gastroenterol.](https://www.ncbi.nlm.nih.gov/pubmed/24127074) 2014 Nov;49(11):1441-52. doi: 10.1007/s00535-013-0900-4. Epub 2013 Oct 15.

**21**. C Xu, C Wu, Y Xia, Z Zhong,  X Liu, J Xu,  F Cui, B Chen,  **OD Røe**, A Li, Y Chen WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo,

*PLoS One. 2013 Aug 1;8(8):e68837. doi: 10.1371/journal.pone.0068837. Print 2013.*

**20.** Cao H, Zhou Q, Wu Y, Li Q, **Røe OD**, Chen Y, Wu Z, Wang D.

[Preoperative Serum Soluble Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin Predict Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Valve Surgery.](http://www.ncbi.nlm.nih.gov/pubmed/23870696)

*Ann Thorac Surg. 2013 Jul 16. doi:pii: S0003-4975(13)00855*

**19.** XF Chen, YQ Liu, **O.D. Røe**, YY Qian, RH Guo, LJ Zhu, YM Yin, YQ Shu

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: A systematic review.

*PLoS One. 2013;8(3):e59314. doi: 10.1371/journal.pone.0059314. Epub 2013 Mar 21*

**18.** [Ye Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Ye%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Li X](http://www.ncbi.nlm.nih.gov/pubmed?term=Li%20X%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Yang J](http://www.ncbi.nlm.nih.gov/pubmed?term=Yang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Miao S](http://www.ncbi.nlm.nih.gov/pubmed?term=Miao%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Wang S](http://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Chen Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Chen%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Xia X](http://www.ncbi.nlm.nih.gov/pubmed?term=Xia%20X%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Wu X](http://www.ncbi.nlm.nih.gov/pubmed?term=Wu%20X%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Zhang J](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Zhou Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhou%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [He S](http://www.ncbi.nlm.nih.gov/pubmed?term=He%20S%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Tan Y](http://www.ncbi.nlm.nih.gov/pubmed?term=Tan%20Y%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Qiang F](http://www.ncbi.nlm.nih.gov/pubmed?term=Qiang%20F%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Li G](http://www.ncbi.nlm.nih.gov/pubmed?term=Li%20G%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed?term=R%C3%B8e%20OD%5BAuthor%5D&cauthor=true&cauthor_uid=23347235), [Zhou J](http://www.ncbi.nlm.nih.gov/pubmed?term=Zhou%20J%5BAuthor%5D&cauthor=true&cauthor_uid=23347235).

MDM2 is a useful prognostic biomarker for resectable gastric cancer.

*Cancer Sci. 2013 May;104(5):590-8. doi: 10.1111/cas.12111. Epub 2013Mar 5*

**17.** Chen Y, Xia X, Wang S, Wu X, Zhang J, Zhou Y, Tan Y, He S, Qiang F, Li A, **Røe OD**, Zhou J. High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil–leucovorin–oxaliplatin treatment in resectable gastric cancer patients

*J Gastroenterol. 2013 Sep;48(9):1034-44. doi: 10.1007/s00535-012-0724-7*

**2012**

**16.** Xi L, Cao H, Zhu J, **Røe OD**, Li M, Wu Y, Wang D, Chen Y.

[OPG/RANK/RANKL Axis in Stabilization of Spontaneously Restored Sinus Rhythm in Permanent Atrial Fibrillation Patients after Mitral Valve Surgery.](http://www.ncbi.nlm.nih.gov/pubmed/23295350)

*Cardiology. 2013;124(1):18-24. doi: 10.1159/000342784. Epub 2012 Dec 28.*

**15.** Liu X, Wang S, Xia X, Chen Y, Zhou Y, Wu X, Zhang J, He S, Tan Y, Qiang F, **Røe OD**, Li G, Zhou J. [Synergistic Role between p53 and JWA: Prognostic and Predictive Biomarkers in Gastric Cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23285001)

*PLoS One. 2012;7(12):e52348. doi: 10.1371/journal.pone.0052348.*

**14.** X Chen, X Zha, W Chen, T Zhu, J Qiu, **OD Røe**, J Li, Z Wang , Y Yin

Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer,

*Biomed Pharmacother. 2013 Feb;67(1):22-30. doi: 10.1016/j.biopha.2012.10.001*

**13.** X Chen, G Ping, S Jin, R Wang, K Yan, **OD Røe**, Y Shu, R Guo,

Case report: Recombinant  human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma,

*J Chemother. 2012 Aug;24(4):231-6. doi: 10.1179/1973947812Y.0000000023.*

**12. O Røe**, AD Szulkin, H Sandeck, E Anderssen, T Amundsen, SE Erlandsen, K Dobra, SH Sundstrøm, Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma.

*PLoS One. 2012;7(8):e40521. doi: 10.1371/journal.pone.0040521. Epub 2012 Aug 8.*

**11.** S Wang, X Wu,J Zhang, Y Chen, J Xu, X Xia, S He, F Qiang, A Li, Y Shu, **OD Røe**, Ga Li,and Jianwei Zhou: CHIP functions as a novel suppressor of tumor angiogenesis with prognostic significance in human gastric cancer.

*Gut. 2013 Apr;62(4):496-508. doi: 10.1136/gutjnl-2011-301522.*

**10.** Wang S, Wu X, Chen Y, Zhang J, Ding J, Zhou Y, He S, Tan Y, Qiang F, Bai J, Zeng J, Gong Z, Li A, Li G, **Røe OD**, Zhou J. Prognostic and predictive role of JWA and XRCC1 expression in gastric cancer

*Clin Cancer Res. 2012 May 15;18(10):2987-96. doi: 10.1158/1078-0432.CCR-11-2863*

**9.** [Chen XF](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chen%20XF%22%5BAuthor%5D), [Wang R](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wang%20R%22%5BAuthor%5D), [Yin YM](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Yin%20YM%22%5BAuthor%5D)**,** [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22R%C3%B8e%20OD%22%5BAuthor%5D), [Li J](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20J%22%5BAuthor%5D), [Zhu LJ](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zhu%20LJ%22%5BAuthor%5D), [Guo RH](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Guo%20RH%22%5BAuthor%5D), [Wu T](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wu%20T%22%5BAuthor%5D), [Shu YQ](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Shu%20YQ%22%5BAuthor%5D).

The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: A retrospective study.

*Biomed Pharmacother. 2012 Jun;66(4):279-84. doi: 10.1016/j.biopha.2012.01.002.*

**2011**

**8.** H Cao, Q Li, M Li, **Røe OD**, Z Wu, Q Zhou, B Cao, B Chen, Y Chen, D Wang: Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation: *Int J Cardiol. 2013 Jul 1;166(3):702-8. doi: 10.1016/j.ijcard.2011.11.099*

**7.** [Cao H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cao%20H%22%5BAuthor%5D), [Wang J](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wang%20J%22%5BAuthor%5D), [Xi L](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xi%20L%22%5BAuthor%5D), [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22R%C3%B8e%20OD%22%5BAuthor%5D), [Chen Y](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chen%20Y%22%5BAuthor%5D), [Wang D](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wang%20D%22%5BAuthor%5D): Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation.

*Circ J. 2011;75(12):2781-8. Epub 2011 Oct 15.*

**6.** I. Tsamardinos, G. Borboudakis, E. G. Christodoulou, **O. D. Røe:**

Chemosensitivity Prediction of Tumours Based on Expression, miRNA, and Proteomics Data*Computational Intelligence Applications in Bioinformatics Workshop (12th EANN(IEEE) /7th AIAI (IFIP), April 2011)*

**2010**

**5.** [Sandeck HP](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Sandeck%20HP%22%5BAuthor%5D), [**Røe OD**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22R%C3%B8e%20OD%22%5BAuthor%5D), [Kjærheim K](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kj%C3%A6rheim%20K%22%5BAuthor%5D), [Willén H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Will%C3%A9n%20H%22%5BAuthor%5D), [Larsson E](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Larsson%20E%22%5BAuthor%5D). Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry.

*Diagn Pathol. 2010 Jul 6;5:47. doi: 10.1186/1746-1596-5-47.*

**4. Røe OD**, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S.

Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.

*Lung Cancer. 2010 Jan;67(1):57-68. doi: 10.1016/j.lungcan.2009.03.016.*

**2009**

**3. OD Røe**, E Anderssen, E Helge, CH Pettersen, KS Olsen, H Sandeck, R Haaverstad, S Lundgren, E Larsson, Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: The emerging gene portrait of the mesothelioma phenotype.

*PLoS One. 2009 Aug 7;4(8):e6554. doi: 10.1371/journal.pone.0006554.*

**2008**

**2. Røe OD**, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case-control study.

*Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025*

**2007**

**1.** Kjaerheim K, **Røe OD**, Waterboer T, Sehr P, Rizk R, Dai HY, Sandeck H, Larsson E, Anderssen A, Boffetta P, Pawlita M. Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples.

*Int J Cancer. 2007 Jun 1;120(11):2459-65.*

**Proceedings (full-paper reviewed)**

|  |
| --- |
| **1.** Christodoulou, E. G., **Røe, O. D**., Folarin, A., & Tsamardinos, I. (2011). Information-Preserving Techniques Improve Chemosensitivity Prediction of Tumours Based on Expression Profiles. 12th Engineering Applications of Neural Networks (EANN) / 7th Artificial Intelligence Applications and Innovations (AIAI) joint conferences, Workshop on Computational Intelligence Applications in Bioinformatics (CIAB 2011). 15-18 September, Corfu, Greece. (pp. 453-462). Springer Boston  **2.** Tsamardinos, I., **Røe, O. D**., & Lagani, V. (2011). Introducing Integrative Causal Analysis for Co-Analyzing Heterogeneous Studies with an Application to Methylation and Gene Expression Mesothelioma Cancer Data. 6th Conference of the Hellenic Society for Computational Biology and Bioinformatics (HSCBB11). October, Patras, Greece. |

**Dissemination-popularized**

19. <https://www.healthtalk.no/alle-artikler/onkologi-oppdaget-molekyler-i-blodet-som-kan-diagnostisere-lungekreft-tidlig/>

18. <https://www.samfunnogokonomi.no/2021/07/er-vi-pa-vei-mot-et-sengelost-hjertelost-og-todelt-helsevesen/>

17. <https://overlegen.digital/overlegen/overlegen-1-2021/forsker-onkolog-og-allsidig-musiker-oluf-dimitri-roe-er-alt-dette/>

16. <https://www.medpagetoday.com/reading-room/asco/lung-cancer/82428>

15. <https://www.adressa.no/meninger/kronikker/2018/06/13/Revolusjonerende-kreftbehandling-ikke-for-alle-16909462.ece>

14. <https://bestprac.no/det-udifferensierte-karsinom-som-ble-et-melanom-hvorfor-re-biopsere-kreft-med-ukjent-utgangspunkt-cup-en-case-studie/>

13. <https://tidsskriftet.no/2018/06/anmeldelser/kreftbiomarkorer-et-gode-eller-et-onde>

12. <http://jamanetwork.com/journals/jamaoncology/article-abstract/2594546>

11. <https://dagensmedicin.dk/asbest-naermiljoeet-oeger-kvinders-risiko-lungehindekraeft/>

10 <https://www.aftenposten.no/meninger/debatt/i/7g3j3/Klassedelt-kreftomsorg-er-opplest-og-vedtatt--Oluf-D-Roe>

9. <https://www.aftenposten.no/meninger/kronikk/Norge-er-sist-ute-med-a-tilby-effektiv-kreftmedisin--Oluf-D-Roe-601992b.html>

8. <https://www.dagensmedisin.no/artikler/2015/11/05/hvorfor-ma-helsevesenet-ikke-privatiseres/>

7. <https://www.nrk.no/ytring/storre-sykehus-gagner-ikke-pasienten-1.12365683>

6. Røe OD, På vei mot en klassedelt kreftomsorg? Presentation at HUNT 27.05.16

<file:///Users/olufdimitriroe/Downloads/20160527_inv_klassedelt-kreftomsorg.pdf>

5. Røe OD, Kan ha funnet nøkkel-molekyl til lungekreft, Interview, Trønder-Avisa, 2015

4. Røe OD, Tror fire ganger flere vil overleve lungekreft, Interview, Adressa, 2015

3. Røe, OD; Falkmer, U.

[Asbestos : Lessons learnt.](http://vbn.aau.dk/da/publications/asbestos(ced54559-4fc9-4e71-81cc-0d307a3d4df6).html) [Pan European Networks: Science and Technology](http://vbn.aau.dk/da/journals/pan-european-networks--science-and-technology(8c6a0711-f44d-4215-b30a-a69cb5a1360e).html), Vol. 17, 2015, s. 226-227.

2. K Kerkentzes, V Lagani, M Vyberg, I Tsamardinos, OD Røe

Skjulte skatter i “gamle” microarrays - Genprofilering portretterer biologi og resistensmekanismer i lungekreft og normalvev. Best Practice, August 2015

1.Røe OD,

Reisebrev fra Kina: Felles forskning på asbest-relatert kreft

http://www.universitetsavisa.no/leserbrev/article38141.ece

**Manuscripts**

1. Submitted PLOS Medicine. The HUNT-Lung-SNP model: genetic variants improve lung cancer risk assessment over clinical models. Olav Toai Duc Nguyen, Ioannis Fotopoulos, Therese Haugdahl Nøst, Maria Markaki, Ioannis Tsamardinos, Vincenzo Lagani, Oluf Dimitri Røe
2. Common microRNAs in pre-diagnostic serum associated with lung cancer in two independent prospective, population-based cohorts: A HUNT study. Ioannis Fotopoulos1, Olav Toai Duc Nguyen2,3 Therese Haugdahl Nøst4,5, Maria Markaki6, Vincenzo Lagani7,8, Robin Mjelle2,5,9, Torkjel Manning Sandanger4, Mattias Johansson10, Pål Sætrom2,9,11, Ioannis Tsamardinos1, Oluf Dimitri Røe2,3,12,13
3. Submitted Scandinavian Journal of Work and Environmental Health: ASBESTOS BAN: DECLINE IN MESOTHELIOMA INCIDENCE NOT SEEN EVEN 40 YEARS LATER Gunnar Hillerdal, MD, PhD, Axel Wannag, MD, and Oluf Dimitri Røe, MD, PhD
4. Submitted Plos one: Novel Predictive Gene and MicroRNA Biomarkers of Chemo-Radiation Resistance in Locally Advanced Adenocarcinoma of the Rectum

Laurids Ø. Poulsen, Vincenzo Lagani, Mikkel Eld, Mette K Yilmaz, Ursula G. Falkmer, **Oluf D. Røe**

1. BE Røe, **OD Røe** Asbestos, Architecture and Cancer: Innovative marketing of asbestos-cement products1956-79.

**Abstracts**

36. Common MicroRNAs in Pre-diagnostic Serum Associated with Lung Cancer in two Cohorts up to Eight Years Before Diagnosis: A HUNT Study. WCLC 2022

*Olav Toai Duc Nguyen1,2, Yannis Fotopoulos3, Therese Haugdahl Nøst4*, *Maria Markaki5,Vincenzo Lagani3,6,7, Ioannis Tsamardinos3,6, Oluf Dimitri Røe1,2*

35. Long-term predictive value of serum PSA values obtained in clinical practice – Results from the Norwegian Prostate Cancer Consortium (NPCC) 2021

34. Utility og HCG as a biomarker of treatment response in advanced urothelial cancer, a population based series at Akershus University Hospital, Norway   
Katarina Puco1, Johan Bjerner2, Stig Müller3, Gunder Magne Lilleaasen3, Haldor Husby4, Mattias Røed-Undlien1, Daniel Heinrich5, Fredrik A. Dahl6, Oluf Dimitri Røe7, Jan Oldenburg1  
*1. Department of Oncology, Akershus University Hospital, Lørenskog, Norway, 2. Fürst Medical Laboratories, Oslo, Norway, 3. Department of Urology, Akershus University Hospital, Lørenskog, Norway, 4. Data Capture, Akershus University Hospital, Lørenskog, Norway, 5. Department of Oncology, Innlandet Hospital Trust, 6. Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway, 7. Cancer Clinic, Levanger Hospital, Levanger, Norway*

**33.** Olav Toai Duc Nguyen**,** Christina Chatzipantsiou**,** Vincenzo Lagani**,** Maria Markaki**,** Hans Fredrik Kvitvang**,** Anna Nordborg**,** Ioannis Tsamardinos, **Oluf Dimitri Røe**

Untargeted Metabolomics Discovers Biomarkers in Serum Years Before Mesothelioma Diagnosis: The HUNT study, IMIG 2020, Brisbane, Australia

**32.** Christos Meristoudis, Louise Andersen Lynggård, Vasiliki Panou, Mogens Vyberg**, Oluf Dimitri Røe**

BAP1 and MTAP in cytology from effusions versus biopsy in malignant mesothelioma diagnosis; Equally good? IMIG 2020, Brisbane, Australia

**31.** O.T. Nguyen, M. Markaki, A. Sharma, C. Chatzipantsiou, V. Lagani, I. Tsamardinos, **O. Røe**

Mass Spectrometry Proteomics Analysis Discovers Biomarkers in Serum Months to Years Before Non-Small Cell Lung Cancer: The HUNT Study

IASLC, Barcelona, Spain, DOI: https://doi.org/10.1016/j.jtho.2019.08.1086

**30.** Olav Toai Duc Nguyen, Maria Markaki, Christina Chatzipantsiou, Animesh Sharma, Vincenzo Lagani, Ioannis Tsamardinos, **Oluf D. Røe**

Proteomics analysis discovers biomarkers in serum months to years before small cell lung cancer: The HUNT study.

ASCO 2019 DOI: 10.1200/JCO.2019.37.15\_suppl.e20095 Journal of Clinical Oncology 37, no. 15\_suppl

**29.** [**Oluf D. Røe**](https://ascopubs.org/author/R%C3%B8e%2C+Oluf+D), [Olav Toai Duc Nguyen](https://ascopubs.org/author/Nguyen%2C+Olav+Toai+Duc), [Klio Lakiotaki](https://ascopubs.org/author/Lakiotaki%2C+Klio), [Ioannis Tsamardinos](https://ascopubs.org/author/Tsamardinos%2C+Ioannis), [Vincenzo Lagani](https://ascopubs.org/author/Lagani%2C+Vincenzo), [Maria Markaki](https://ascopubs.org/author/Markaki%2C+Maria)

Improvement of lung cancer risk prediction adding SNPs to the HUNT Lung Cancer Model: A HUNT Study.

ASCO 2019 DOI: 10.1200/JCO.2019.37.15\_suppl.e20696 Journal of Clinical Oncology 37, no. 15\_suppl

**28.** Christina Chatzipantsiou, Vincenzo Lagani, Maria Markaki,  OT Duc Nguyen, I Tsamardinos, HF Kvitvang, A Nordborg, R Mjelle, **OD Røe**

Metabolomics signature in serum months to years before thoracic cancer: A HUNT study

ECCB 2018 17th European Conference on Computational Biology

September 8-12 2018, Athens Greece

**27.** Vasiliki Panou, Christos Meristoudis, Ulla M. Weinreich, **Oluf D. Røe**, Mogens Vyberg. IMPACT OF CALRETININ IMMUNOHISTOCHEMISTRY AND THE IMIG GUIDELINES IN THE MALIGNANT MESOTHELIOMA DIAGNOSIS

IMIG 2018, 2-5th May, Ottawa, Canada

**26. OD Røe,** Ø Omland, V Panou, A Wannag

Asbestos consumtion, Eternit and pleural mesothelioma in Norway and Denmark: Similar populations, different stories.

IMIG 2018, 2-5th May, Ottawa, Canada

**25.**V Panou, UM Weinreich, J Bak, M Vyberg, C Meristoudis, O Omland, **OD Roe**, J Hansen

Gender differences in asbestos exposure and disease location in 327 patients with mesothelioma

European Respiratory Journal 2017 50: PA4294; DOI: 10.1183/1393003.congress-2017.PA4294

**24.** **OD Røe**, M. Markaki, I. Tsamardinos, A. Langhammer, V. Lagani, K. Hveem.

A Validated Clinical Lung Cancer Risk-Prediction Model for Light-, Heavy- and Ex-Smokers: the HUNT Lung Cancer Model, IASLC 18th World Conference on Lung Cancer, Oct. 2017, Yokohama, Japan

**23. OD Røe,** R. Mjelle, H.F. Kvitvang, I. Tsamardinos, M. Markaki3O.T.D. Nguyen, V. Lagani

Metabolic Biomarkers in Serum for the Early Diagnosis of Lung Cancer: First Results from the Cancer-Biomarkers in HUNT Initiative, IASLC 18th World Conference on Lung Cancer, Oct. 2017, Yokohama, Japan

**22.** Panou V, Vyberg M, Meristoudis C, Omland Ø, Weinreich UM ,Hansen J, **Røe OD**

Malignant mesothelioma in 91 Danish women - the environmental asbestos exposure

ASCO, Chicago, USA June 2017, J Clin Oncol (Poster 8560)

**21. Røe OD**, Lagani V, Kvitvang HF, Markaki M, Tsamardinos I, Mjelle R

*Metabolomics signature in serum months to years before thoracic cancer: The HUNT study.* ASCO, Chicago, USA June 2017, J Clin Oncol (Abstr e23059)

**20.** Panou V, Nielsen I, Sørensen JB, **Røe OD,**

Pemetrexed as first or second line in 112 Danish patients.ASCO, Chicago, USA June 2016, J Clin Oncol 34, 2016 (suppl; abstr e20084)

**19**. **OD Røe**, Robin Mjelle, Maria Markaki, Trygve Andreassen, Vincenzo Lagani, Ioannis Tsamardinos, Tone Bathen, Pål Sætrom, Kristian Hveem

Serum microRNAs/enriched pathways in lung cancer 1-4 years before diagnosis: A pilot study from the HUNT Biobank, Norway.

ASCO, Chicago, USA June 2016, J Clin Oncol 34, 2016 (suppl; abstr 11539)

**18.** Robin Mjelle, Maria Markaki, Trygve Andreassen, Vincenzo Lagani, Ioannis Tsamardinos, Tone Bathen, Pål Sætrom, Kristian Hveem, **OD Røe**

Serum biomarkers in mesothelioma 1-3 years before diagnosis

-a pilot study IMIG Birmingham, UK May 2016

**17.** Kerkentzes K, Mjelle R, **Røe OD**

MicroRNA miR-615-3p and let-7b targets multiple key pathways overexpressed in lung adenocarcinoma

IASLC, Sept. 2015, Denver, USA

**16.** Zhibin G, Hiroshima K, **Røe OD**, Morinaga K

Asbestos textile production linked to malignant peritoneal and pleural mesothelioma in women: Analysis of 28 cases in Southeast China

IMIG 2014, Cape Town

**15.** Panou V, Omland Ø, Vyberg M, **Røe OD**

Overrepresentation of malignant peritoneal mesothelioma among females in a cohort of 296 danish patients

IMIG 2014, Cape Town

**14.** R Mjelle, T Andreassen, V Lagani, K Kerkentzes, I Tsamardinos, TF Bathen, E Larsson, **OD Røe**, “Hunting” for lung-cancer / mesothelioma early diagnostic biomarkers: results of a pilot analysis from the Cancer-Biomarker-HUNT study.

IMIG 2014, Cape Town

**13. Oluf Dimitri Røe,** Bjørn Edin Røe

AC- International Asbestos Cement Review 1955-78: The asbestos industry using world-renowned architects to showcase and increase popularity of asbestos construction materials.

IMIG 2014, Cape Town

**12.** Panou Vasiliki, Meristoudis Christos, **Røe Oluf Dimitri**

Malignant mesothelioma in Aalborg, North Denmark. Pathology records of the Aalborg University Hospital reveal 562 cases and a 13-fold increase in four decades (European Congress of Pathology).

**11.** Xiaofeng Chen, **Oluf D. Røe**

Postoperative leukopenia is an independent prognostic factor in resectable gastric cancer patients (ASCO, 2014).

**10.** Wu Chen, Xiaofei Zhi, Duan Chen, Yijiang Chen, **Oluf Dimitri Røe**

DNA repair suppression and effect of cisplatin in mesothelioma and lung cancer cell lines. ASCO, J Clin Oncol 31, 2013 (suppl; abstr e13542)

**9.** Dimitris Vainas, **Oluf Dimitri Røe**, Vincenzo Lagani

Comparative evaluation of Affymetrix and Illumina genome-wide expression data in Pleural Mesothelioma, Proceedings of the 7th conference of the Hellenic Society for Computational Biology & Bioinformatics - HSCBB12 FORTH, Heraklion, Crete, Greece, 4-6/10/2012

**8**. **Oluf Dimitri Røe**, Kostas Kerkentzes

Differentially expressed genes of major lung tumour subtypes and normal lung tissue. Proceedings of the 7th conference of the Hellenic Society for Computational Biology & Bioinformatics - HSCBB12

FORTH, Heraklion, Crete, Greece, 4-6/10/2012

**7.** Gao Zhibin, **Oluf Dimitri Røe**

Mesothelioma cluster in a medium sized hospital in South-East China: Relations to asbestos exposure and clinicopathological findings, IMIG, Boston, USA, 2012

**6.** Helmut Paul Sandeck, **Oluf Dimitri Røe**, Kristina Kjærheim, Helena Willén, Erik Larsson Re-evaluation of malignant mesothelioma: similar results in a Norwegian and a Japanese study despite of different approaches IMIG 2010, Kyoto, Japan

**5. Oluf Dimitri Røe**, Endre Anderssen, Helmut Sandeck, Erik Larsson, Mark Ladanyi Genome-Wide Profile of Pleural Mesothelioma versus Parietal Pleura: Confirmation of the Gene Portrait of the Mesothelioma Phenotype. IMIG 2010, Kyoto, Japan

**4. Røe OD**, Anderssen E, Amundsen T, Sandeck H, Sundstrøm S

Acquired Chemo-resistance in mesothelioma: a case report of a long-term survivor and gene expression findings related to aquired resistance. IMIG 2010, Kyoto, Japan

**3. O. D. Roe**, E. Anderssen, E. Helge, C. H. Pettersen, H. Sandeck, E. Larsson, S. Lundgren

Overexpression of a set of genes in mesothelioma versus parietal pleura may explain its chemo- and radio-resistance. ASCO 2008, Chicago, USA Abstract No: 13506 J Clin Oncol 26: 2008 (May 20 suppl; abstr 13506)

**2. Oluf D. Røe,** Endre Anderssen, Helmut Sandeck, Erik Larsson, Steinar Lundgren.

Gene expression reflecting resistance and targets in mesothelioma: a general model of tumour resistance? IMIG 2008, Amsterdam, Holland

**1. OD Røe,** J Creaney, S Lundgren, E Larsson, H Sandech, P Boffetta, TI Nilsen, B Robinson, K Kjaerheim

Pre- diagnostic Soluble Mesothelin Related Protein (SMRP), CA125, CYFRA 21-and risk of mesothelioma: a case-control study. IMIG 2006, Chicago, USA

**Oral presentations (mesothelioma and lung cancer)**

21. Nguyen, OTD; Fotopoulos, Y; Markaki, M; Lagani, V; Tsamardinos, I; **Røe, OD**

The HUNT Lung Cancer Model outperforms the current European (NELSON) criteria for detecting lung cancer.

Abstract. Helsetjenesteforskningskonferansen, 2023

20. Wu, Y; Kunst, N; Kristiansen, IS; Strand, TE; **Røe, OD**; Ashraf, H; Burger, EA

Cost-effectiveness of lung cancer screening for high-risk ever-smokers in Norway: a model- based analysis based on NELSON trial outcomes

Abstract. Helsetjenesteforskningskonferansen, 2023

19. **Genetic Variants of HUNT Lung Cancer Model Improve Lung Cancer Risk Assessment over clinical models**

*Olav Toai Duc Nguyen1,2, Yannis Fotopoulos3, Therese Haugdahl Nøst4*, *Maria Markaki5,Vincenzo Lagani3,6,7, Ioannis Tsamardinos3,6, Oluf Dimitri Røe1,2*  WCLC 2022

18. V. Panou , A. Louw, W. M. Szejniuk , C. Meristoudis, S. M. Chai, L. Lynggård Andersen, A. Birbaneh Asghari, M. Vyberg, J. Hansen, J. Creaney, **O. D. Røe**

**BAP1 loss predicts longer survival for mesothelioma patients treated with pemetrexedbased chemotherapy.**

Abstract 22157 ERS 2020

**17.** Oluf Dimitri Røe, MD, Maria Markaki, Ioannis Tsamardinos, Vincenzo Lagani, Jesper Holst Pedersen, M, Zaigham Saghir, Haseem Ashraf.

**“Reduced” HUNT Lung Cancer Model for predicting lung cancer in the prospective Danish Lung Cancer Screening Trial -**

**comparison with the NLST.**

Journal of Thoracic Oncology, 2018, vol 13, issue 10 Supplement, Page S426

**16.** C Chatzipantsiou, V Lagani, Maria Markaki, OT Duc Nguyen, I Tsamardinos, HF Kvitvang, A Nordborg, R Mjelle, **OD Røe**

**Metabolomics signatures in serum years before thoracic cancer: The HUNT study**

**2nd International NTNU Symposium on**

**Current and Future Clinical Biomarkers of Cancer**

June 14th-15th 2016, Trondheim, Norway

**15.** Sofie B. Dalsgaard , Else Toft Würtz, Johnni Hansen, **Oluf D. Røe**, Øyvind Omland. **CHILDHOOD SCHOOL ATTENDANCE NEAR AN ASBESTOS CEMENT PLANT AND ADULT MESOTHELIOMA RISK**

IMIG 2018, 2-5th May, Ottawa, Canada

**14.** Hvidsten M, **Røe OD**

**Asbestos disease research in former Soviet Union and Russia; Literature comparisons with United Kingdom and Japan.**

IMIG 2018, 2-5th May, Ottawa, Canada

**13. Røe OD**

Cancer-Biomarkers in HUNT study: Early diagnostic poly-markers in lung cancer and mesothelioma **1st International NTNU Symposium on**

**Current and Future Clinical Biomarkers of Cancer: Innovation and Implementation**

June 16th-17th 2016, Trondheim, Norway

**12.** Panou V, Mogens V, Meristoudis C, **Røe OD**

BAP-1 cancer syndrome associated malignancies were not detected among 558 Danish patients with malignant mesothelioma,

IMIG, May 2016, UK

**11.** Panou V, Omland Ø, Meristoudis C, Hoffmann L, **Røe OD**

Degree of asbestos exposure predisposes to pleural or peritoneal disease in women: Malignant mesothelioma in a female population in North Jutland, Denmark

IASLC, sept. 2015, Denver, USA

**10.** Panou V, Omland Ø, Langhoff MD, Meristoudis C, Weinreich UM, **Røe OD**

Malignant mesothelioma in women in the Region of North Jutland, Denmark;

Non-Occupational asbestos exposure in more than 50% of the cases.

IMIG 2014, Cape Town, South Africa

**9.** 3rd World Congress on Cancer Science and Therapy, San Francisco, October 2013

Asbestos Cancer and Biomarker HUNT

**8.** IMIG2012, Boston, USA

Cell cycle checkpoint genes and homologous recombinational repair are overexpressed in malignant pleural mesothelioma

**7.** The 3rd Erling Seeberg symposium, June 2012 in Trondheim and Ørland, Norway

Fanconi anemia genes, RHINO and other cell cycle checkpoint genes are overexpressed in malignant pleural mesothelioma

**6.** IMIG 2010, Kyoto, Japan

Genome-Wide Profile of Pleural Mesothelioma versus Parietal Pleura: Confirmation of the Gene Portrait of the Mesothelioma Phenotype.

**5.** IMIG 2008, Amsterdam, Holland

Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets

**4.** IMIG 2008, Amsterdam, Holland

Identification of new targets by genome wide profiling

**3.** IMIG 2006, Chicago, USA

Microarray of normal mesothelium and mesothelioma—visceral and parietal pleura has distinct gene expression profile—consequences for oncogenesis of mesothelioma?

**2.** IMES-TR, 2005, Antalya, Turkey

SMRP (Soluble Mesothelin Related Protein), CYFRA 21-1 and CA125 in serum 1-30 years before mesothelioma diagnosis: a case-control study.

**1.** Nordisk Lungekongress 2005, Trondheim, Norway

Risk of mesothelioma is not associated with the presence of SV40 antibodies or genomic fragments of SV40 in pre-diagnostic serum samples in Norway.